Loss of deep cerebellar nuclei neurons in the 3xTg-AD mouse
and protection by an anti-Aβ antibody fragment

Gisela Esquerda-Canals*, Joaquim Martí*, Geovanny Rivera-Hernández*, Lydia Giménez-Llort† and Sandra Villegas*

(*): Protein Folding and Stability Group. Dpt. de Bioquímica i Biologia Molecular (†)
Dpt.de Biologia Cel.lular, de Fisiologia i d’Immunologia. Unidad de Citologia i
d’Histologia; (†) Dpt.de Psiquiatra i Medicina, i Institut de Neurociències;
Universitat Autònoma de Barcelona, Bellaterra, 08193 Barcelona, Spain.

Running title: 3xTg-AD mouse cerebellum protected by scFv-h3D6


1 These authors made equally important contributions to this study.

2 To whom correspondence should be addressed (e-mail sandra.villegas@uab.cat). Departament de Bioquímica i Biologia Molecular, Unitat de Biociències, Universitat Autònoma de Barcelona, 08193 Cerdanyola del Vallès, Spain. Tel. 34 93 5914258, Fax. 34 93 5911264

Abbreviations used: AD, Alzheimer disease; DCN, deep cerebellar nuclei; GCs, granular cells; PCs, Purkinje cells; scFv, single chain variable fragment.
Abstract

The therapeutic potential of scFv-h3D6 has recently been shown in the 3xTg-AD mouse. A clear effect on Aβ-oligomers and certain apolipoproteins in the brain was found, but no effect was seen in the cerebellum. Here, cellular vulnerability of the 3xTg-AD cerebellum is described for the first time, together with its protection by scFv-h3D6. Neuron depletion in the DCN was regionally variable and followed a mediolateral axis of involvement that was greatest in the fastigial nucleus, lesser in the interpositus, and negligible in the dentate nucleus. Interestingly, a sole and low intraperitoneal dose of scFv-h3D6 protected 3xTg-AD DCN neurons from death. Further studies might provide interesting information about both the potential of scFv-h3D6 as a therapeutic agent and the role of the cerebellum in AD.

Key words: ScFv-h3D6, Immunotherapy, Alzheimer disease, Cerebellum, DCN neurons
INTRODUCTION

Alzheimer’s Disease International estimated that 36 million people were living with dementia in 2010, with most cases attributable to Alzheimer disease (AD). Projections of the prevalence of the disease indicated that there may be 66 million cases by 2030 and 115 million by 2050. As a consequence, AD is considered to be a twenty-first century pandemic.

Neuritic plaques composed of β-amyloid (βA) peptides, as well as neurofibrillary tangles of hyperphosphorylated tau-protein, are the histopathological hallmarks of AD. Although brain regions are the structures primarily affected in AD, the occurrence of diffuse βA deposits has also been reported in the molecular layer of the cerebellar cortex and, to a lower extent, in the granule cell layer. Additionally, Purkinje cell (PC) loss and synaptic dysfunction are heightened as the disease progresses.

The triple-transgenic mouse model of AD (3xTg-AD), harboring two human transgenes causing early onset AD (PS1M146V and APPSwe) and a mutant form of tau (taup301L), mimics both βA plaques and tau neurofibrillary tangles following a regional and temporal involvement homologous to humans. At 4 months of age, βA accumulates in cortical regions and initiates progression to the hippocampus, whereas tau hyperphosphorylation develops after βA accumulation (at ~ 12-15 months), beginning in limbic structures and extending later through cortical regions. Since the Alzheimer’s Disease International 2011’s report claimed the necessity for early intervention in AD, our studies were performed with 5-month-old animals. Females were selected because they exhibit significantly greater Aβ burden and larger behavioral deficits than age-matched males.

We recently used this model to show that immunotherapy with an anti-Aβ antibody fragment is a potential tool for the treatment of AD (Ref. FENS & Giménez-Llort submitted to MAbs). Specifically, we constructed a single-chain variable fragment
(scFv), scFv-h3D6, from the humanized monoclonal antibody AAB-001 (mAb-h3D6, bapineuzumab). An advantage of the use of such fragments compared to the use of complete antibodies is that Fc-mediated activation of microglia cannot occur. Therefore, use of scFv-h3D6 could avoid some of the undesirable effects reported in Phase 3 clinical trials for bapineuzumab. In fact, a single intraperitoneal dose of scFv-h3D6 reversed BPSD-like behaviors, improved long- and short-term learning and memory deficits, globally decreased Aβ-oligomers in the cortex and olfactory bulb, and recovered the non-pathological levels of some apolipoproteins in the cortex (apoE and apoJ) and hippocampus (apoE) (Ref. FENS & Giménez-Llort submitted to MAb). However, no differences in the concentration of these molecules were found in the cerebellum.

Since affectation of human cerebellum has been described in late phases of the disease, we wondered when neuronal vulnerability in the 3xTg-AD cerebellum, either in the cortex or the deep nuclei, could appear. A dramatic death in young 3xTg-AD deep cerebellar nuclei neurons was found and, more exciting, we successfully tested the capability of scFv-h3D6 for preventing it.
RESULTS

The numbers of granule cells (GCs) and Purkinje cells (PCs), as well as cellular density, in each cerebellar cortex region analyzed were similar between 3xTg-AD and NTg mice (Table 1). However, differences were found when comparing the area of GCs’ layer at the vermis of the untreated (or treated) NTg with that of the untreated 3xTg-AD animals (Table 1), which showed a mild, although significant, decrease. It is noteworthy that scFv-h3D6 treatment exerted a protective effect on the size of GCs’ layer because no differences were found between treated 3xTg-AD group and NTg groups.

Similarly, the areas of the fastigial and interpositus nucleus were smaller in the 3xTg-AD mice than in the NTg one, but no differences were found in the dentate nuclei (Table 1). These differences also occurred, and in the same direction, when both cell number and cell density were compared (Table 1). Since changes are bigger in the cell number than in the areas, we below refer to the total number of cells rather than to the cell density.

... could did not exert an effect in the cerebellar cortex.

In contrast to the cerebellar cortex, the loss of neurons was dramatically evident at the cerebellar nuclei (Fig. 1 and Table 1). The number of neurons in the fastigial nucleus was significantly lower in the 3xTg-AD group, with a mean value 24% that of the NTg mice (p=0.050). Interestingly, the treatment with scFv-h3D6 allowed for the maintenance of 61% of the cells of the 3xTg-AD compared to the untreated NTg (p=0.028), and 67% compared to the treated NTg (p=0.014). No significant difference was found between treated and untreated NTg groups. In any case, it is fairly clear that scFv-h3D6 treatment protected fastigial nucleus neurons from death, although its beneficial effect did not reach non-pathological conditions. Photomicrographs of sagittal
sections at the level of the fastigial nucleus show the affectation involving of these DCN neurons and the robust pronounced action of scFv-h3D6 on cell viability (Fig. 2).

When cell counts were done in the interpositus nucleus, a similar effect was found (Fig. 1 and Table 1). The cell bodies percentage in the 3xTg-AD was 58% that of the NTg (\(p=0.014\)), whereas treatment allowed for the survival of 87% of the cells. This value is not significantly different to the initial cell count (untreated NTg) (\(p=0.243\)) and, in consequence, a complete protection of neurotoxicity could be interpreted. Although the treated NTg group showed higher cell viability that the untreated one (127%), there was no significant difference among these experimental groups (\(p=0.114\)). As a consequence, scFv-h3D6 treatment completely protected interpositus nucleus neurons from death in the 3xTg-AD mouse. Photomicrographs of sagittal sections at the level of the interpositus nucleus show the affectation involving of these DCN neurons and the recovery of cell viability by scFv-h3D6 (Fig. 2).

When the dentate nucleus was considered, no significant effect of the genotype on the number of neurons was observed (Fig. 1 and Table 1). In consonance, treatment could did not exert an effect in this area region.

Several conclusions emerged from these data: (I) the loss of cells in the 3xTg-AD cerebellum depends on the neuronal type examined; (II) macroneuron depletion in the DCN was regionally variable, being greatest in the fastigial nucleus, lesser in the interpositus, and not occurring negligible in the dentate nucleus; (III) the administration of scFv-h3D6 protected 3xTg-AD DCN neurons from death, as seen five days after injection of a single dose; and (IV) although the single injection of 100 µg of scFv-h3D6 completely rescued 3xTg-AD interpositus neurons to the level of the NTg mice, this dose was not sufficient to completely rescue fastigial neurons, which were the most affected initially.
DISCUSSION

We had previously shown that an antibody fragment, the single-chain variable fragment scFv-h3D6, has the ability to prevent the toxicity induced by the Aβ peptide in human neuroblastoma cell-cultures. Additionally, we recently demonstrated the benefits of scFv-h3D6 in 5-month-old female 3xTg-AD animals, which corresponds to early stages of the disease (Ref. FENS & Giménez-Llort submitted to MAb).

The 3xTg-AD mouse brain develops molecular and histological alterations characteristic of AD, following a regional and temporal affection involving homologous to humans. Because some studies revealed the affection involving cerebellum in late phases of the disease, study of the affection involving the disease progression in the 3xTg-AD mouse’s cerebellum is of interest. Other mouse models that are also linked to PS1 mutations showed cerebellar Aβ deposition in the form of neuritic plaques and Purkinje cell loss. A few Aβ plaques were detected in the molecular layer at 6 months, but loss of synaptic contacts between parallel fibers and dendritic spines of Purkinje cells, and degeneration of granule cells, required 12 months.

Although cerebellar neurons have been reported to be more resistant to soluble oligomeric Aβ than other neurons in the brain, we wondered when neuronal vulnerability in the 3xTg-AD cerebellum could appear. We focused the study in both the cerebellar cortex and deep nuclei by counting different cellular populations. Plausibly, we did not observe significant differences in the cerebellar cortex because we studied a very early stage of the disease progression. In contrast, the 3xTg-AD cerebellar nuclei showed a gradient of neural loss through the mediolateral axis, with the fastigial nucleus the most affected area, followed by the interpositus nucleus, and dentate nucleus not being affected. Although several studies have demonstrated the direct
anatomic connection from fastigial nucleus to encephalic regions as amygdala, hippocampus and cerebral cortex, as well as the projection through thalamus of interpositus and dentate nucleus to cerebral cortex, this is the first time that deep cerebellar nuclei neurons are shown to be affected at early stages of AD progression.

Even more exciting, however, is the finding that scFv-h3D6 is able to protect 3xTg-AD DCN neurons from death, although the extent of protection was variable. While administration of scFv-h3D6 completely rescued 3xTg-AD interpositus neurons to the non-pathological level of the NTg mice, this dose was not sufficient to completely rescue fastigial neurons, which were initially the most affected ones. It is important to note that, in contrast to other published studies, i.e., intranasal administration of 1.5 mg/ml scFv twice a week for 14 weeks, in the current work 100 µg of scFv-h3D6 were intraperitoneally administered and the effect assessed five days after this low and sole dose.

In conclusion, we described the Aβ-induced death of deep cerebellar nuclei neurons at early stages of the disease progression in the 3xTg-AD mouse model and their rescue by a single, low dose of scFv-h3D6. Further studies increasing dose and using other stages of the disease would provide interesting information about both the therapeutic potential of scFv-h3D6 and the role of the cerebellum in Alzheimer disease.

MATERIALS AND METHODS

ScFv-h3D6 was recombinantly expressed in E. coli and purified as previously described (Rivera-Hernández submitted to MAbs). Lipopolysaccharides (LPS), the major endotoxins of gram-negative bacteria, were removed from the protein by using Detoxi-Gel Endotoxin Removing columns (Thermo Scientific).
Triple-transgenic 3xTg-AD mouse harboring PS1<sub>M146V</sub>, APP<sub>Swe</sub> and tau<sub>P301L</sub> transgenes was genetically engineered at the University of California Irvine. Sixteen 5-month-old females animals from the Spanish colony of homozygous 3xTg-AD and wild-type non-transgenic (NTg) mice (n=8 each group) were used in the present study. Standard laboratory conditions (food and water ad lib, 22 ± 2 ºC, 12 h light: dark cycle starting at 08:00) were used and all the experiments were carried out in accordance with the requirements of the Ethical Committee of Universitat Autònoma de Barcelona.

Animals were randomly treated with a single intraperitoneal dose of 100 μg scFv-h3D6 or vehicle (PBS-buffer) (n=4). After five days, animals were anesthetized with sodium pentobarbital (50 mg/kg) and perfused through the heart with 4% paraformaldehyde in PBS-buffer (pH 7.4). Tissue processing was developed as regular procedures from our laboratory. The blocks containing the cerebellum were sectioned serially at 10 μm in the sagittal plane and one of every six sections was saved. Sections were stained with hematoxylin-eosin or cresyl violet.

Neurons were counted in representative sections of every mediolateral parcellation of the cerebellar cortex separately: vermis, paravermis, and hemispheres. GCs and PCs were scored in lobules (I to X) at vermis and paravermis, whereas simplex, ansiform and paramedian lobules were considered at the hemispheres. In the deep cerebellar nuclei (DCN), macroneurons (body cell bigger than 20 μm in diameter) were separately counted at the level of the fastigial, interpositus and dentate nucleus. The number of GCs and PCs were counted separately in vermis and paravermis (lobules I to X). Criteria for scoring them included both morphological and staining properties. Small, darkly stained and densely packed cells were considered as GCs. PCs were counted on the bases of several assumptions such as size, the morphological characteristics of the pericarion and distinctive stain properties. These macroneurons were considered as present if they possessed large pear-shape cell body and nucleus with the presence of a distinct nucleolus.
The quantity of deep nuclear neurons was independently determined at the level of the fastigial, the interpositus and the dentate nuclei. Quantification of DCN neurons deserves special attention because it is known that two cellular types, small and large, coexist. To obtain reliable data, those neurons with a cell body smaller than 20 µm in diameter were rejected.

Photographic material was digitally captured by a CCD-IRIS color video camera (Sony, Japan) coupled to a Zeiss Axiosphot microscope. The digitized images were processed with the Adobe Photoshop software.

The statistical significance of the results was evaluated with the non-parametric Mann-Whitney U-test. A “p” value equal or lower than 0.05 was considered statistically significant.

Acknowledgements: The animals used in the present study come from the colony of homozygous 3xTg-AD and wild-type NTg mice established by Lydia Giménez-Llort at the Universitat Autònoma de Barcelona, Spain, from progenitors kindly provided by Frank M. LaFerla, Department of Neurobiology and Behavior, University of California Irvine, California, USA.

Funding: This work was supported by FMM-2008; FISPI10-00975, -00265 & -00283; SGR2009-00761 & -42271. G.R-H is supported by a MAEC-AECI fellowship (Spanish government) and G.E-C. by a PIF (UAB, Spain) fellowship.

The authors state that “there are no potential conflicts of interest in our submission”.

Author's draft version
References


Figure 1: Depletion of deep cerebellar nuclei neurons in the 3xTg-AD mouse cerebellum and recovery by scFv-h3D6 treatment. Cell numbers from fastigial, interposed and dentate nuclei were determined. Black, untreated NTg group; Striped, scFv-treated NTg group; White, untreated 3xTg-AD group; Squared, scFv-treated 3xTg-AD group. Results are expressed by means ± S.E.M. *significant vs untreated NTg group (p≤0.05); **significant vs untreated 3xTg-AD group (p<0.03). Significance values were calculated via Mann-Whitney test.

Figure 2: Illustrative photomicrographs of sagittal sections. At the level of the fastigial and interpositus nuclei the affectationinvolvement of DCN neurons and its protection by scFv-h3D6 is shown. Bar is 50 µm.

Table 1: Numerical values of the neuronal populations from cerebellar cortex and nuclei (PC, GC and DCN macroneurons) quantification.

Cell number, area (mm²), and density (number of cells/mm²) were quantified. Results are expressed by means ± S.E.M. *significant vs untreated NTg group (p≤0.05); **significant vs untreated 3xTg-AD group (p≤0.05). Treated NTg significances vs other groups are omitted as no significant effects were found upon treatment. Significance values were calculated via Mann-Whitney test. *Length refers to that of the monolayer (Purkinje Cells Layer) in mm and cellular density refers the number of PC per unit of length.
<table>
<thead>
<tr>
<th></th>
<th>NTg/-</th>
<th>NTg/+</th>
<th>3xTg-AD/-</th>
<th>3xTg-AD/+</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Purkinje cells</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vermis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cell number</td>
<td>788.5±20.5</td>
<td>748.5±53.9</td>
<td>758.3±35.5</td>
<td>789.3±36.3</td>
</tr>
<tr>
<td>Length(^a)</td>
<td>27.3±0.5</td>
<td>27.1±0.5</td>
<td>24.7±1.5</td>
<td>28.3±0.9</td>
</tr>
<tr>
<td>Cellular density(^a)</td>
<td>28.9±0.5</td>
<td>27.5±1.7</td>
<td>30.8±1.6</td>
<td>27.9±1.1</td>
</tr>
<tr>
<td>Paravermis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cell number</td>
<td>685.5±58.6</td>
<td>725.5±36.9</td>
<td>706.3±39.6</td>
<td>681.3±16.9</td>
</tr>
<tr>
<td>Length(^a)</td>
<td>24.9±2.1</td>
<td>25.1±0.8</td>
<td>24.7±1.0</td>
<td>26.1±0.6</td>
</tr>
<tr>
<td>Cellular density(^a)</td>
<td>27.6±0.3</td>
<td>29.0±1.8</td>
<td>28.6±0.8</td>
<td>26.1±0.6</td>
</tr>
<tr>
<td><strong>Granule cells</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vermis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cell number</td>
<td>58192±3464</td>
<td>56312±178</td>
<td>47815±2634</td>
<td>56389±2085</td>
</tr>
<tr>
<td>Area</td>
<td>3.4±0.2</td>
<td>3.4±0.0</td>
<td>2.9±0.0*</td>
<td>3.2±0.1**</td>
</tr>
<tr>
<td>Cellular density</td>
<td>17214±237</td>
<td>16827±127</td>
<td>16608±626</td>
<td>17581±513</td>
</tr>
<tr>
<td>Paravermis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cell number</td>
<td>41946±4850</td>
<td>40263±2553</td>
<td>42010±4619</td>
<td>44609±3625</td>
</tr>
<tr>
<td>Area</td>
<td>2.8±0.0</td>
<td>2.4±0.0</td>
<td>2.6±0.1</td>
<td>2.7±0.1</td>
</tr>
<tr>
<td>Cellular density</td>
<td>15024±592</td>
<td>16807±932</td>
<td>16145±650</td>
<td>16297±1012</td>
</tr>
<tr>
<td><strong>DCN macroneurons</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fastigial</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cell number</td>
<td>31.89±2.35</td>
<td>29.13±2.53</td>
<td>7.50±1.44*</td>
<td>19.46±2.50*/**</td>
</tr>
<tr>
<td>Area</td>
<td>0.37±0.04</td>
<td>0.35±0.03</td>
<td>0.15±0.01*</td>
<td>0.27±0.03**</td>
</tr>
<tr>
<td>Cellular density</td>
<td>88.61±7.98</td>
<td>82.96±2.62</td>
<td>60.44±1.08*</td>
<td>71.06±3.76**</td>
</tr>
<tr>
<td>Interpositus</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cell number</td>
<td>27.83±2.73</td>
<td>35.47±2.53</td>
<td>16.25±0.89*</td>
<td>24.23±2.96**</td>
</tr>
<tr>
<td>Area</td>
<td>0.49±0.05</td>
<td>0.57±0.04</td>
<td>0.36±0.02*</td>
<td>0.46±0.02**</td>
</tr>
<tr>
<td>Cellular density</td>
<td>57.20±2.26</td>
<td>62.81±5.85</td>
<td>44.86±1.77*</td>
<td>56.30±3.11**</td>
</tr>
<tr>
<td>Dentate</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cell number</td>
<td>22.89±1.82</td>
<td>25.58±1.94</td>
<td>22.00±2.18</td>
<td>22.25±2.15</td>
</tr>
<tr>
<td>Area</td>
<td>0.35±0.04</td>
<td>0.41±0.01</td>
<td>0.37±0.03</td>
<td>0.38±0.05</td>
</tr>
<tr>
<td>Cellular density</td>
<td>66.47±2.34</td>
<td>62.04±5.26</td>
<td>59.39±1.54</td>
<td>62.54±10.08</td>
</tr>
</tbody>
</table>